Conduit Pharmaceuticals (CDT) announces the filing of two groundbreaking patents for tapinarof, VTAMA, including a dual active cocrystal, ...

Lina Manufacturing Limited, the pharmaceutical manufacturing arm of Sunshine Holdings PLC, unveiled its new brand identity – a powerful logo that reflects the company’s evolution, vision, and ...

Royalty Pharma (RPRX) announced the appointment of Vlad Coric to the company’s board of directors, effective immediately. Vlad Coric is the ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Trump has announced 25% tariffs on cars and car parts imported into the US US President Donald Trump has again singled out Ireland's pharmaceutical industry as a target for tariffs. Trump was ...

Looking ahead, this article highlights the key trends expected to shape the regulatory landscape of pharmaceutical manufacturing in 2025. Regulatory agencies—including the U.S. Food and Drug ...

There remains much uncertainty about these measures, however. As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news.

Hypera SA (HYPMY) achieved a 9% increase in sellout for 2024, with significant growth in the institutional non-retail market at 26%. The company successfully launched over 50 new products in 2024 ...

Good morning, ladies and gentlemen. Welcome to Hypera Pharma's Earnings Call for the Fourth Quarter of 2024. We have with us Mr. Breno Oliveira, CEO; Ramon Silva, CFO; and Adalmario Couto ...

(MENAFN- The Rio Times) Hypera Pharma reported a steep 74.2% drop in fourth-quarter profit from continuing operations, falling to R$79.5 million ($13.9 million) compared to the same period last year.

SAO PAULO, March 21 (Reuters) - Brazilian drugmaker Hypera (HYPE3.SA), opens new tab plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's (NOVOb.CO ...